FDA Clearance Tracker · P190032-S005
FoundationOne Liquid CDx (F1 Liquid CDx)
Last checked: Nov 20, 2026Latest source record: May 3, 2023 (this decision)Source: openFDAMethods & limitations
Decided
May 3, 2023
Approved
Time to decision
261 days
Received Aug 15, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P190032-S005
- Device name
- FoundationOne Liquid CDx (F1 Liquid CDx)
- Applicant
- Foundation Medicine, Inc.
- Applicant location
- Boston, MA
- Received
- Aug 15, 2022
- Decided
- May 3, 2023
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P190032
Device type
- Device type
- Next generation sequencing oncology panel, somatic or germline variant detection system (PQP)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval to include a companion diagnostic indication for EGFR exon 20 insertions in patients with non-small cell lung cancer who may benefit from treatment with EXKIVITY® (mobocertinib).
Source documents
Other decisions for Foundation Medicine, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- FoundationOne CDx (F1CDx)PMA supplement
P170019-S060 · Decided May 27, 2026 · 614 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
- FoundationOne Liquid CDxPMA supplement
P190032-S029 · Decided May 27, 2026 · 490 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
- FoundationOne CDxPMA supplement
P170019-S054 · Decided Jan 16, 2025 · 209 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.